DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Tools I Use
Real-Time Market Scanner
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Recommended Platform
Professional Trading Workflow
Charts • Watchlists • Multi-broker tools
Built for active traders
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Insider Weekly · Merlintrader
Insider trading this week: the 20 biggest buys and 20 biggest sells
Who bought and who sold shares of their own company — by dollar value — in the week of June 29 to July 3, 2026.
Insider trading: how to read this ranking
Methodology. Data pulled from Finviz Elite’s insider register (SEC Form 4 filings for executed transactions and Form 144 for proposed sales). Transactions are filtered on trade dates in the week of June 29 – July 3, 2026 and ranked by dollar value. For buys we include only open-market purchases (“Buy”). For sells we include both executed sales (“Sale”) and proposed sales via Form 144 (badge Form 144), which signal an intent to sell and not always a completed transaction. A useful principle: insider buys usually carry a single meaning (confidence in the stock), while sells can have many causes (tax planning, diversification, scheduled 10b5-1 plans, venture-capital fund distributions after an IPO) and do not by themselves imply a negative view. Data sources: Finviz Elite and SEC EDGAR (Form 4). See all our deep dives on Merlintrader.
Top 20 insider buys of the week
Open-market purchases, ranked by dollar value. The week is dominated by a few strong convictions (Hartree on Hudson Technologies, the Wallbox board after the restructuring, the double buy on Nuvectis) and by several small and micro caps.
| # | Ticker | Company | Insider | Role | Date | Shares | Price | Value USD |
|---|---|---|---|---|---|---|---|---|
| 1 | BBD | Banco Bradesco SA ADR | Bueno Julio Cesar | CLO and Executive Officer | Jul 1 | 110,441 | $18.10 | $1,998,983 |
| 2 | RH | RH | ALBERINI CARLOS | Director | Jun 29 | 11,388 | $160.90 | $1,832,322 |
| 3 | HDSN | Hudson Technologies Inc | Hartree Partners, LP | 10% Owner | Jul 1 | 288,111 | $5.88 | $1,695,101 |
| 4 | HDSN | Hudson Technologies Inc | Hartree Partners, LP | 10% Owner | Jul 2 | 271,302 | $5.97 | $1,619,212 |
| 5 | WBX | Wallbox N.V | Richer Marc Sabe | Director | Jun 30 | 501,361 | $2.72 | $1,364,504 |
| 6 | WBX | Wallbox N.V | Aguera Pedro Alonso | Director | Jun 30 | 501,361 | $2.72 | $1,364,504 |
| 7 | WBX | Wallbox N.V | Mera Francisco Jose Riberas | Director | Jun 30 | 501,361 | $2.72 | $1,364,504 |
| 8 | HDSN | Hudson Technologies Inc | Hartree Partners, LP | 10% Owner | Jun 30 | 204,789 | $5.68 | $1,162,894 |
| 9 | NVCT | Nuvectis Pharma Inc | Mosseri Marlio Charles | 10% Owner | Jun 30 | 50,000 | $18.32 | $916,000 |
| 10 | WBX | Wallbox N.V | Escorsa Enric Asuncion | Chief Executive Officer | Jun 30 | 325,885 | $2.72 | $886,929 |
| 11 | FGBI | First Guaranty Bancshares Inc | Smith Edgar R. III | Director | Jun 30 | 74,846 | $10.61 | $794,116 |
| 12 | CREX | Creative Realities Inc | MILLS RICHARD C | Chief Executive Officer | Jun 30 | 200,000 | $3.50 | $700,000 |
| 13 | FUND | Sprott Focus Trust Inc | GEORGE W WHITNEY | Senior Portfolio Manager | Jun 29 | 71,664 | $9.63 | $690,124 |
| 14 | AVO | Mission Produce Inc | Pack Jay A | Director | Jun 30 | 40,000 | $12.10 | $484,000 |
| 15 | PSBD | Palmer Square Capital BDC Inc | Bicknell Martin C | 10% Owner | Jul 1 | 40,000 | $10.57 | $422,800 |
| 16 | PSBD | Palmer Square Capital BDC Inc | Bicknell Martin C | 10% Owner | Jul 2 | 40,000 | $10.55 | $422,000 |
| 17 | NVCT | Nuvectis Pharma Inc | BENTSUR RON | Chairman & CEO | Jun 30 | 12,500 | $20.00 | $250,000 |
| 18 | FTH | Faeth Therapeutics Inc | STEPHENSON BRIAN C | Chief Financial Officer | Jun 30 | 7,803 | $24.25 | $189,240 |
| 19 | INLF | INLIF Ltd | HRT FINANCIAL LP | 10% Owner | Jun 29 | 2,919,237 | $0.06 | $186,831 |
| 20 | BOLD | Boundless Bio Inc | TANG KEVIN | 10% Owner | Jul 1 | 71,612 | $2.49 | $178,314 |
Top 20 insider sells of the week
Executed sales (Sale) and proposed sales (Form 144), ranked by dollar value. Large holders (VC/healthcare funds and private equity, post-IPO) and 10b5-1 plans of top managers at big-cap tech and semiconductors dominate.
| # | Ticker | Company | Insider | Role | Type | Date | Shares | Price | Value USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics Inc | Fairmount Funds Management LLC | Director | Sale | Jul 1 | 3,553,410 | $84.43 | $300,014,406 |
| 2 | HNGE | Hinge Health Inc | Insight Holdings Group, LLC | 10% Owner | Sale | Jun 29 | 1,466,667 | $82.83 | $121,489,333 |
| 3 | NET | Cloudflare Inc | Matthew Prince | Officer | Form 144 | Jul 1 | 471,486 | $246.31 | $116,131,717 |
| 4 | UTHR | United Therapeutics Corp | MARTINE ROTHBLATT | Director | Form 144 | Jul 1 | 209,000 | $541.83 | $113,242,470 |
| 5 | ALAB | Astera Labs Inc | MAR 2011 CHILDRENS TRUST U/A D | Director | Form 144 | Jul 1 | 170,000 | $483.02 | $82,113,400 |
| 6 | ALAB | Astera Labs Inc | ALBA 2003 LIVING TRUST | Director | Form 144 | Jul 1 | 150,000 | $483.02 | $72,453,000 |
| 7 | AMAT | Applied Materials Inc | Gary Dickerson | Officer | Form 144 | Jun 29 | 100,000 | $700.00 | $70,000,000 |
| 8 | BABA | Alibaba Group Holding Ltd ADR | EVANS J. MICHAEL | President | Sale | Jun 29 | 720,000 | $94.95 | $68,360,495 |
| 9 | PRM | Perimeter Solutions Inc | WINDACRE PARTNERSHIP LLC | 10% Owner | Sale | Jun 30 | 1,875,000 | $33.90 | $63,562,500 |
| 10 | HNGE | Hinge Health Inc | Insight Venture Partners X, L. | 10% Owner | Form 144 | Jun 29 | 732,444 | $80.00 | $58,595,520 |
| 11 | SNOW | Snowflake Inc | Dageville Benoit | Officer | Form 144 | Jul 2 | 190,819 | $254.64 | $48,590,150 |
| 12 | HNGE | Hinge Health Inc | Insight Venture Partners (Caym | 10% Owner | Form 144 | Jun 29 | 600,613 | $80.00 | $48,049,040 |
| 13 | ABNB | Airbnb Inc | Gebbia Joseph | Director | Sale | Jun 29 | 294,903 | $148.43 | $43,771,373 |
| 14 | MU | Micron Technology Inc | April S. Arnzen | Officer | Form 144 | Jul 1 | 40,000 | $1083.87 | $43,354,934 |
| 15 | ANET | Arista Networks Inc | Andreas Bechtolsheim | 10% Owner | Form 144 | Jul 1 | 260,000 | $166.62 | $43,321,200 |
| 16 | AMAT | Applied Materials Inc | DICKERSON GARY E | President and CEO | Sale | Jun 29 | 58,321 | $700.36 | $40,845,895 |
| 17 | WTTR | Select Water Solutions Inc | Crestview Partners II SES Inve | Shareholder | Form 144 | Jul 1 | 2,000,000 | $19.98 | $39,960,000 |
| 18 | ANET | Arista Networks Inc | Andreas Bechtolsheim | 10% Owner | Form 144 | Jul 2 | 240,000 | $159.99 | $38,397,600 |
| 19 | AIP | Arteris Inc | BAYVIEW LEGACY, LLC | 10% Owner | Form 144 | Jul 1 | 700,000 | $48.59 | $34,013,000 |
| 20 | CACC | Credit Acceptance Corp | Allan V. Apple | 10% Owner | Form 144 | Jul 2 | 50,000 | $657.12 | $32,856,000 |
The companies, in brief — and the next catalyst
A short description of every company involved and the next potentially market-moving event known as of publication.
Who bought (buy side)
Buy · Banco Bradesco (BBD) · ~$18.2B
Banco Bradesco
One of Brazil’s largest private-sector banks, listed in New York as an ADR. Q1 2026 beat estimates (non-GAAP EPS $0.12, +25% YoY; revenue $7.5B). The buy came from a senior executive (CLO).
Next catalyst: Q2 2026 results (early August), the path of Brazil’s Selic rate and credit quality.
Buy · RH (Restoration Hardware) (RH) · ~$3.2B
RH (Restoration Hardware)
Premium home furnishings and design retailer with a luxury positioning. High short interest (over 30% of float). Just launched the RH Estates collection. Purchase by a director.
Next catalyst: Next quarterly report (fiscal, expected early September) and the direction of U.S. rates/housing.
Buy · Hudson Technologies (HDSN) · ~$252M
Hudson Technologies
U.S. small cap in the recovery, reclamation and sale of refrigerants (HFC/HFO gases). 10% owner Hartree Partners bought ~$4.48M over three days: four of the twenty buys are theirs. Guided Q2 revenue to $73-76M and won a DLA contract extension to November 29, 2026.
Next catalyst: Q2 2026 results (early August), summer-season HFC pricing, HFO licensing developments.
Buy · Wallbox N.V. (WBX) · ~$75M
Wallbox N.V.
Spanish EV-charging company (hardware and software). Its court-approved financial restructuring became effective this week (stock ~+22%). Right after, three directors and the CEO bought shares: four of the twenty buys are Wallbox.
Next catalyst: Execution of the post-restructuring plan, next quarterly report, liquidity and margin updates.
Buy · Nuvectis Pharma (NVCT) · ~$617M
Nuvectis Pharma
Clinical-stage precision-oncology biotech. Lead program NXP900 (SRC/YES1 inhibitor, in Phase 1b including with osimertinib in EGFR-mutated NSCLC) and NXP800 (ARID1a ovarian cancers). Double insider buy (10% owner and Chairman & CEO) right after a discounted $100M offering that sank the stock ~-35%.
Next catalyst: Preliminary readout of the NXP900 Phase 1b expected in summer 2026.
Buy · First Guaranty Bancshares (FGBI) · ~$165M
First Guaranty Bancshares
Small Louisiana regional bank. Q1 2026 net income of $2.7M ($0.14 per share). Purchase by a director.
Next catalyst: Q2 2026 results (late July), net interest margin and loan quality.
Buy · Creative Realities (CREX) · ~$54M
Creative Realities
U.S. micro cap in digital signage and in-store marketing technology (screens, software, analytics). Just priced a $12M offering at $3.50; the CEO bought 200,000 shares at the offering price.
Next catalyst: Q2 2026 results, deployment of the offering proceeds and new retail contracts.
Buy · Sprott Focus Trust (FUND) · ~$284M
Sprott Focus Trust
Value-oriented closed-end equity fund managed by Sprott. Declared a Q2 distribution of $0.1424 per share. The buy is by the fund’s senior portfolio manager.
Next catalyst: Next quarterly distribution and the evolution of the discount/premium to NAV.
Buy · Mission Produce (AVO) · ~$1.1B
Mission Produce
Vertically integrated grower and distributor of avocados (and mangoes), with operations in Peru and Mexico. Hurt by low avocado prices but guiding to a sharp 2H EBITDA rebound. Purchase by a director.
Next catalyst: Fiscal quarterly report (expected September), seasonality and avocado pricing.
Buy · Palmer Square Capital BDC (PSBD) · ~$326M
Palmer Square Capital BDC
Business development company (private/leveraged credit). Expanded its share buyback by $30M (through June 2027). The 10% owner bought over two days.
Next catalyst: Q2 2026 results and the next quarterly distribution (dividend).
Buy · Faeth Therapeutics (FTH) · ~$591M
Faeth Therapeutics
Oncology biotech (formerly Sensei Biotherapeutics; FTH ticker since June 2026, ~$200M raised). Lead candidate PIKTOR, an all-oral combination of serabelisib (PI3K-alpha) and sapanisertib (mTORC1/2). Buy ratings from H.C. Wainwright ($60 PT) and Baird. Purchase by the CFO.
Next catalyst: Topline of the PIKTOR Phase 2 in advanced endometrial cancer expected in 2H 2026.
Buy · INLIF Ltd (INLF) · < $1M
INLIF Ltd
Micro/penny industrial stock. Announced a 1-for-200 reverse split (-23% premarket). The buy comes from HRT Financial, a high-frequency trading firm: likely market-making activity rather than a conviction signal.
Next catalyst: Effectiveness of the 1:200 reverse split and listing-compliance steps.
Buy · Boundless Bio (BOLD) · ~$56M
Boundless Bio
Oncology biotech focused on ecDNA (extrachromosomal DNA); its clinical program BBI-940 was discontinued for insufficient data. Announced an all-stock merger with Serapha Bio (expected new ticker AATD) with a $230M private placement and a ~$44-48M pre-closing cash dividend to holders. The buy is by Kevin Tang (Tang Capital).
Next catalyst: Serapha merger close expected in Q4 2026 and the special pre-closing cash dividend.
Who sold (sell side)
Sell · Oruka Therapeutics (ORKA) · ~$5.1B
Oruka Therapeutics
Dermatology biotech. Lead candidate ORKA-001 (ultra-long half-life anti-IL-23, potential once-yearly dosing) posted strong Week 16 data in plaque psoriasis (PASI 100 of 63.5% vs 4.8% placebo). The ~$300M sale is by Fairmount, a longtime healthcare fund and major holder: monetization on stock strength, not a view on the drug.
Next catalyst: Longer-term efficacy data: Week 28 and 52-week follow-up on a subset, expected in 2H 2026.
Sell · Hinge Health (HNGE) · ~$6.5B
Hinge Health
Digital musculoskeletal-care platform (remote physical therapy), fresh off its 2025 IPO. Three of the twenty sells are Insight Partners entities converting Class B into Class A and distributing under an August 2025 10b5-1 plan: typical post-IPO flow. The company raised its 2026 revenue guidance (up to $824M).
Next catalyst: Q2 2026 results (early August), remaining lock-up expirations, member growth.
Sell · Cloudflare (NET) · ~$86.1B
Cloudflare
Leader in edge internet infrastructure (CDN, security, zero-trust). The proposed sale (Form 144) is by co-founder and CEO Matthew Prince, typically under scheduled 10b5-1 plans. Recent launches: AI bot-traffic defenses and Pay Per Use monetization for publishers.
Next catalyst: Q2 2026 results (late July/early August) and adoption of the new AI/pay-per-crawl products.
Sell · United Therapeutics (UTHR) · ~$23.6B
United Therapeutics
Profitable biotech focused on pulmonary hypertension (Tyvaso franchise) and bioengineered organs. Proposed sale (Form 144) by CEO Martine Rothblatt. Key catalyst already delivered: the pivotal TETON-1 and TETON-2 studies hit their primary endpoint in idiopathic pulmonary fibrosis (IPF). Recently announced the Thymmune acquisition (up to $300M).
Next catalyst: Regulatory filing/decision (sNDA) for Tyvaso in IPF at the FDA; Q2 2026 results.
Sell · Astera Labs (ALAB) · ~$69.7B
Astera Labs
Semiconductors for connectivity in AI data centers (PCIe/CXL/Ethernet). Two proposed sales (Form 144, ~$155M) come from family trusts tied to a director: post-IPO wealth diversification. The stock corrected (~-9% on the week) on profit-taking in semis.
Next catalyst: Q2 2026 results (early August), hyperscaler AI capex, ramp of new products.
Sell · Applied Materials (AMAT) · ~$478.8B
Applied Materials
The world’s largest maker of semiconductor manufacturing equipment. CEO Gary Dickerson appears twice: a proposed sale (Form 144, $70M) and an executed one ($40.8M), typically under a 10b5-1 plan. The stock fell (~-7%) in the chip sell-off.
Next catalyst: Fiscal quarter (mid-August), foundry capex cycle, AI demand and China/export dynamics.
Sell · Alibaba Group (BABA) · ~$230.8B
Alibaba Group
Chinese e-commerce and cloud giant, listed as an ADR. Executed sale by President J. Michael Evans. In the background, a $600M non-prosecution agreement with the U.S. DOJ over alleged illicit sales on the platform.
Next catalyst: Fiscal quarter (mid-August), Alibaba Cloud growth and AI monetization, U.S.-China backdrop.
Sell · Perimeter Solutions (PRM) · ~$5.5B
Perimeter Solutions
Maker of fire retardants and suppressants and specialty chemicals, with multi-year contracts with CAL FIRE and the Defense Logistics Agency. Q1 2026 well above estimates; Specialty Products +128% YoY thanks to MMT. The sale is by 10% owner WindAcre Partnership.
Next catalyst: Q2 2026 results (early August) and, seasonally relevant, the intensity of the U.S. summer fire season.
Sell · Snowflake (SNOW) · ~$90.2B
Snowflake
Cloud platform for data and AI (data warehouse/lakehouse). Proposed sale (Form 144) by an officer. Continues to sign enterprise partnerships (e.g., data clean rooms for retail media).
Next catalyst: Quarterly results (fiscal, expected late August), consumption growth and AI product adoption.
Sell · Airbnb (ABNB) · ~$89.8B
Airbnb
Global platform for short-term rentals and experiences. Executed sale by co-founder and director Joseph Gebbia. Recent news: a court ruled Airbnb must face a Los Angeles lawsuit over alleged price gouging.
Next catalyst: Q2 2026 results (early August), summer travel season, rollout of the new Experiences/services.
Sell · Micron Technology (MU) · ~$1,100B
Micron Technology
Memory giant (DRAM/NAND) and a key beneficiary of high-bandwidth memory (HBM) demand for AI. Proposed sale (Form 144) by an officer. The segment is supported by massive investment plans from Asian chipmakers.
Next catalyst: Fiscal quarter (late September), DRAM/NAND pricing and the HBM ramp for AI.
Sell · Arista Networks (ANET) · ~$201.5B
Arista Networks
Leader in high-performance networking for AI/cloud data centers. Two proposed sales (Form 144) by co-founder and 10% owner Andreas Bechtolsheim on different days. The stock took part in the tech/AI sell-off.
Next catalyst: Q2 2026 results (early August), hyperscaler AI capex and margin trajectory.
Sell · Select Water Solutions (WTTR) · ~$2.5B
Select Water Solutions
Water management services and infrastructure for U.S. oil & gas (and chemicals). Proposed sale by private equity firm Crestview Partners. Developing commercial-scale iodine facilities from produced water.
Next catalyst: Q2 2026 results, completion activity in U.S. basins and progress on the iodine project.
Sell · Arteris (AIP) · ~$1.6B
Arteris
Semiconductor IP provider (network-on-chip interconnects used in SoCs for automotive, AI and data centers). A proposed sale (Form 144) of 700,000 shares by Bayview Legacy pushed the stock -17%.
Next catalyst: Q2 2026 results, new design wins and royalties from chips in production.
Sell · Credit Acceptance (CACC) · ~$6.9B
Credit Acceptance
Consumer finance company specialized in subprime auto lending through U.S. dealers. Proposed sale (Form 144) by a 10% owner. Just extended a credit facility on better terms.
Next catalyst: Q2 2026 results, delinquency/recovery trends and funding costs.
Bottom line
The buy side this week speaks the language of small caps and founders: refrigerants (Hudson), EV charging (Wallbox), precision biotech (Nuvectis, Faeth), plus regional banks, BDCs and closed-end funds. The sell side is driven instead by large-holder monetizations and scheduled plans from the leadership of AI/semiconductor big caps (Cloudflare, Astera Labs, Applied Materials, Micron, Arista) and by post-IPO fund distributions (Hinge Health, Astera Labs). As always, a single insider does not make a trend: the ranking is there to show where flows concentrate, not to suggest trades.
Disclaimer. This content is for educational and informational purposes only. It is not financial advice, a solicitation, or a recommendation to buy or sell any security, consistent with U.S. SEC guidance. Insider transactions (SEC Form 4/Form 144) are public facts but do not predict future share performance: buys and especially sells can have many motivations (tax planning, personal liquidity, scheduled 10b5-1 plans, fund distributions). Data is provided by Finviz and may contain delays or inaccuracies; always verify the original filings on the SEC’s EDGAR. Each reader should do their own research and consult a licensed advisor. Full disclaimer: https://www.merlintrader.com/disclaimer/
Merlintrader · Insider Weekly · Finviz Elite / SEC data · Week of June 29 – July 3, 2026